Comments
Glenmark Pharmaceuticals has gained 2.4 per cent.
CLSA has given it a "buy" rating and a target price of Rs 1,060.
It says the drugmaker is at the cusp of a revival with a pick-up in US approvals.
The stock has 24 "buys", six "holds" and one "sell" rating.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.